Does prostate cancer increase the risk of venous thromboembolism, including deep‑vein thrombosis and pulmonary embolism?

Yes, Prostate Cancer Significantly Increases the Risk of Venous Thromboembolism

Men with prostate cancer have a substantially elevated risk of developing venous thromboembolism (VTE), including both deep vein thrombosis (DVT) and pulmonary embolism (PE), with the risk being approximately 50% higher compared to men without prostate cancer. 1

Magnitude of Risk

The evidence demonstrates clear and consistent elevation in VTE risk among prostate cancer patients:

• Overall VTE risk increases by 48-56% in men with prostate cancer compared to matched controls without cancer 1
• The risk is highest in the first 6 months after diagnosis (2.5-fold increase), then decreases but remains elevated at approximately 1.6-fold at 5 years 1
• Absolute incidence rates: 6.54 per 1000 person-years in prostate cancer patients versus 4.27 per 1000 person-years in men without prostate cancer 1
• Both DVT and PE risks are similarly elevated, with adjusted hazard ratios of approximately 1.48 for DVT and 1.47 for PE 1

Risk Stratification According to Guidelines

While prostate cancer is recognized as a cancer type, it is classified in the intermediate-risk category (risk score = 1) for chemotherapy-associated VTE in the validated Khorana risk prediction model 2, 3. This places it in the "genitourinary" high-risk category, though not in the very highest risk group (which includes stomach and pancreatic adenocarcinomas with risk score = 2).

However, this guideline-based risk stratification applies primarily to ambulatory patients receiving chemotherapy. The actual VTE risk in prostate cancer is multifactorial and depends heavily on treatment modality.

Treatment-Specific Risk Factors

Androgen Deprivation Therapy (ADT)

ADT substantially amplifies VTE risk beyond that of prostate cancer alone:

• Men receiving GnRH agonists have a 67% increased risk of thromboembolic disease (HR 1.67) 4
• Surgically castrated men have a 61% increased risk (HR 1.61) 4
• The risk is highest among patients who switch from anti-androgen monotherapy to GnRH agonists, with PE risk increasing 2.55-fold, rising from HR 2.52 in year 1 to HR 4.05 in year 2 4
• Interestingly, anti-androgen monotherapy appears protective with lower DVT risk (HR 0.49) 4
• ADT increases risk through multiple mechanisms including endothelial damage and alterations in coagulation factors 2

Surgical Treatment

Even curative surgical treatment increases VTE risk:

• Men undergoing curative treatment have elevated risks for DVT (SIR 1.73) and PE (SIR 2.03) 5
• The 3-month post-surgical VTE incidence is 0.33%, with 2-year incidence of 0.81% 6

Surveillance

Even men on active surveillance without active treatment show increased VTE risk: DVT (SIR 1.27) and PE (SIR 1.57) 5, suggesting that prostate cancer itself, independent of treatment, is prothrombotic.

Clinical Risk Factors That Amplify VTE Risk

Age ≥75 years is a critical risk factor (SHR 2.16 for TE, SHR 3.67 for VTE) 6

Elevated inflammatory markers, specifically C-reactive protein ≥0.35 mg/dL (SHR 2.91) 6

High comorbidity burden: Approximately 29% of VTE episodes occur in patients with high comorbidity levels, with clinical interaction between comorbidity and prostate cancer 7

Disease characteristics:

• Metastatic disease confers 4-13 times higher VTE risk than localized disease 2
• High Gleason scores (≥8) are associated with worse outcomes when VTE occurs 6
• Pathological venous invasion increases VTE risk 5-fold (SHR 5.13) 6

Prognostic Impact

VTE occurrence in prostate cancer patients is not merely a complication—it is an independent predictor of mortality 8, 9. The mortality rate is 2-3 fold higher in cancer patients with VTE compared to those without VTE 9. This reflects both fatal PE complications and potentially more aggressive underlying disease biology 2.

Clinical Implications for Practice

Risk Assessment

Clinicians should systematically assess VTE risk in all prostate cancer patients, particularly:

• Before initiating ADT (especially GnRH agonists)
• In patients ≥75 years old
• Those with elevated CRP or high comorbidity burden
• Patients with metastatic or high-grade disease
• During the first 6 months after diagnosis

Prophylaxis Considerations

According to ESMO and international guidelines 2, 8:

For hospitalized prostate cancer patients with reduced mobility: Prophylaxis with LMWH, UFH, or fondaparinux is recommended [1B evidence]

For surgical patients:

• Prophylaxis with LMWH or UFH is recommended for major cancer surgery [1A evidence] 8, 2
• Extended prophylaxis for 4 weeks may be indicated in high-risk patients with low bleeding risk [2B evidence] 8
• Newer options include rivaroxaban or apixaban after initial LMWH/UFH, though evidence remains limited [weak recommendation] 10

For ambulatory patients on ADT: Routine prophylaxis is not recommended for all patients [1B evidence] 8, but should be considered in high-risk individuals based on the Khorana score and individual risk factors.

Important Caveat

Prostate cancer is NOT classified among the very highest risk cancers (like pancreatic, gastric, or brain tumors) in guideline risk stratification models 2, 3. However, the substantial body of population-based evidence demonstrates clinically meaningful VTE risk elevation, particularly with ADT and in older patients with comorbidities. The decision to use prophylactic anticoagulation must balance this moderate-to-high VTE risk against bleeding risk on an individual basis.